Transdermal fentanyl was released in Germany in 1995. From October 1996 to February
1998 transdermal treatment was documented for 1005 patients (506 men and 499 women …

Fentanyl has been incorporated into a transdermal therapeutic system (TTS) containing a
rate-limiting membrane that provides constant release of the opioid. TTS fentanyl provides …

This pilot study evaluated the efficacy and side effects of a combination of initial patient-
controlled analgesia (PCA) for dose-finding with transdermal fentanyl administration. Twenty …

This open prospective study evaluated the combination of initial dose titration with patient-
controlled analgesia (PCA) and long-term treatment with transdermal fentanyl in 50 cancer …

Five cancer patients experienced satisfactory pain relief for periods of 3-156 days using
continuous transdermal delivery of the narcotic fentanyl. The patients, aged 16-68 years …

The long-term therapy of 51 patients using transdermal fentanyl was evaluated. The
transdermal therapy was performed for 158 days (range, 15–855 days). The need for …

Background Controlled-release morphine (MST) given twice daily provides a simpler and
more convenient treatment regimen than 4-hourly opioid administration for the control of …

BACKGROUND:: The equipotency ratio of transdermal (TD) fentanyl to oral morphine has
been established as 1: 100; for buprenorphine TD, a ratio of 1: 75 has been proposed …

Pain is a feature of many cancers, particularly in the advanced stages at which the palliative
care approach to symptom control achieves the best outcomes. The holistic approach …

The objective of this international, multicenter, open-label trial was to assess the efficacy and
safety of up to 12 months of therapy with transdermal therapeutic system (TTS) fentanyl in …